Compare Gilead Sciences, Inc. (GILD) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs L3Harris Technologies Inc — how do they compare? Gilead Sciences, Inc. trades at $135.25 (market cap $163.51B), while L3Harris Technologies Inc trades at $284.34 (market cap $53.43B). The key difference: Gilead Sciences, Inc. is far larger — about 3.1× L3Harris Technologies Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | LHX | |
|---|---|---|
Market Cap | $163.51B | $53.43B |
Sector | Health | Industrials |
52-Week High | $155.80 | $378.48 |
52-Week Low | $108.22 | $263.09 |
Enterprise Value | $178.05B | $64.20B |
Dividend Yield | 2.49% | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
LHX trades at $283.29, down 2.32% on the day, amid a bearish technical signal but strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, with revenue growing to $21.87B in 2025 and net income reaching $1.61B. Recent contract wins from the U.S. Space Force and Army highlight ongoing defense demand, while analyst consensus remains strongly bullish with a $367.50 price target.
The outlook for LHX is positive given its record backlog and government contracts, though risks include execution on growth initiatives and defense budget volatility. With a P/E of 31.14, the stock trades at a premium to historical averages, but institutional support and dividend payments provide stability. Near-term performance hinges on Q2 2026 earnings due next.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
